Clinical Trial Update: An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension [Phase 4]

View source ↗

Summary

An open-label extension study evaluating the safety of continued subcutaneous Remodulin (treprostinil) in pulmonary arterial hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Remodulin (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: WITHDRAWN